NTRA News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

NT

Mkt Cap

$53.25B

Volume

N/A

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy?Stanley Druckenmiller's Duquesne family office has maintained Natera as its largest holding for 8 consecutive quarters. The medical diagnostics company uses liquid biopsy technology for cancer detection and other applications, showing strong growth with 57% year-over-year increase in oncology tests and 38% revenue growth. Despite persistent losses, the company has strong cash reserves and is projected to approach profitability by 2027. However, the stock has surged 87% in the past year with a lofty price-to-sales ratio of 17.The Motley Fool · Sep 14, 2026

Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia)Billionaire investor Stanley Druckenmiller holds positions in Amazon and Alphabet for AI infrastructure exposure, but his largest U.S. stock holding is Natera, a genetic diagnostics company that has returned approximately 10x since his initial investment in Q3 2022. Druckenmiller sold his Nvidia position in early 2024 due to valuation concerns and now holds Taiwan Semiconductor Manufacturing as his AI semiconductor bet instead.The Motley Fool · Sep 8, 2026

Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead.Billionaire investor Stanley Druckenmiller has dramatically reduced his exposure to megacap tech stocks, holding only Amazon as a minor position (0.32%) among the Magnificent Seven and completely exiting Alphabet. Instead, he's concentrating his $3 billion portfolio in biotech (Natera at 21%), semiconductors (Taiwan Semiconductor at 5.7%), and emerging markets, while adding positions in semiconductor suppliers like Broadcom, Micron, and STMicroelectronics.The Motley Fool · Aug 8, 2026

Natera Positioned To Capture Growing $20 Billion MRD Opportunity-AnalystWilliam Blair initiated coverage on Natera (NASDAQ: NTRA), highlighting the company's strong positioning in the minimal residual disease (MRD) testing market. Analyst Andrew Brackmann estimates Natera generated close to $1 billion in MRD revenue in 2025 with expected growth exceeding 40% in 2026. The MRD market, valued at over $20 billion, is still in early stages with mid- to high-single digit penetration. Natera's competitive advantages include early-mover status, clinical evidence, and strong market share in NIPT (over 50%), positioning it well against competitors as the market expands.Benzinga · Apr 14, 2026

Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip SurgeryNatera announced promising results from a prospective study showing its Signatera molecular residual disease (MRD) test can identify older women with early-stage ER+/HER2- breast cancer who can be managed with primary endocrine therapy without surgery. The study of 43 women over 70 demonstrated 100% negative predictive value for MRD-negative patients and 100% longitudinal sensitivity for detecting progression. NTRA shares rose 5.26% to $196.68 on the news, with analysts maintaining a Buy rating and $248.06 average price target.Benzinga · Mar 31, 2026

3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next DecadeExelixis, a U.S.-based biotech company specializing in cancer treatments, is positioned for market-beating returns through its growing pipeline beyond its blockbuster cabozantinib drug. The company reported 57.9% EPS growth in 2025 and recently received FDA approval for zanzalintinib for metastatic colorectal cancer. With zanzalintinib in four phase 3 trials and strategic partnerships with major pharma companies, Exelixis aims to become a top-five solid tumor oncology company.The Motley Fool · Feb 28, 2026

Billionaire Stanley Druckenmiller Is Betting Big on These 2 StocksBillionaire investor Stanley Druckenmiller holds two major positions in his portfolio: Natera (NTRA), a genetic testing company with strong revenue growth and expanding margins despite current losses, and Taiwan Semiconductor Manufacturing (TSM), which benefits from AI demand but faces challenges with rising capital expenditures that will limit future cash-flow margin expansion.The Motley Fool · Feb 22, 2026

Esoteric Testing Research Report 2026 - Global $41.5+ Bn Market Trends, Opportunities, and Forecasts to 2031The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.GlobeNewswire Inc. · Jan 30, 2026

Non-Invasive Prenatal Testing Market is expected to generate a revenue of USD 9.83 Billion by 2031, Globally, at 17.01% CAGR: Verified Market Research®The global Non-Invasive Prenatal Testing (NIPT) market is projected to grow at a CAGR of 17.01% from 2024 to 2031, reaching USD 9.83 billion from USD 2.8 billion in 2024. Growth is driven by rising demand for early fetal detection, advancements in next-generation sequencing technology, and increased adoption of safer prenatal testing methods. However, high costs, regulatory hurdles, and limited insurance coverage remain significant market restraints, particularly in emerging markets.GlobeNewswire Inc. · Jan 9, 2026

Reproductive Genetics Market Size to Reach USD 16.67 Billion in 2032 Amid Increasing Demand for Genetic TestingThe global reproductive genetics market is projected to grow from USD 7.31 billion in 2025 to USD 16.67 billion by 2032, with a CAGR of 12.5%. Growth is driven by rising demand for genetic testing, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), though ethical and legal challenges continue to limit expansion. North America leads with 40.5% market share, while Asia Pacific is the fastest-growing region.GlobeNewswire Inc. · Dec 30, 2025

NT

NTRANatera, Inc. Common Stock

NTRA

Pay with—

Available Balance0.00

Your PositionYou don't own any NTRA yet.

Related Tickers

Earnings